Premium
Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes
Author(s) -
Chaplin Steve,
Wilding John
Publication year - 2013
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1076
Subject(s) - dapagliflozin , medicine , type 2 diabetes , diabetes mellitus , adverse effect , intensive care medicine , pharmacology , endocrinology
Dapagliflozin (Forxiga) is the first SGLT2 inhibitor licensed for the treatment of type 2 diabetes. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Professor John Wilding discusses its potential role in treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom